Sharon Mates is Chairman and CEO of Intra-Cellular Therapies, Inc.. Currently has a direct ownership of 0 shares of ITCI, which is worth approximately $0. The most recent transaction as insider was on Mar 10, 2023, when has been sold 20,565 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
100.0% 3M change
100.0% 12M change
Total Value Held $0

Sharon Mates Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 10 2023
BUY
Exercise of conversion of derivative security
-
20,565 Added 1.76%
1,150,874 Common Stock
Mar 09 2023
BUY
Grant, award, or other acquisition
-
41,770 Added 3.44%
1,172,079 Common Stock
Feb 24 2023
SELL
Open market or private sale
$1,062,407 $47.03 p/Share
22,590 Reduced 2.01%
1,100,309 Common Stock
Feb 24 2023
BUY
Exercise of conversion of derivative security
$97,800 $3.26 p/Share
30,000 Added 2.59%
1,130,309 Common Stock
Feb 23 2023
BUY
Exercise of conversion of derivative security
-
22,590 Added 1.97%
1,122,899 Common Stock
Feb 21 2023
SELL
Open market or private sale
$1,338,096 $48.05 p/Share
27,848 Reduced 2.47%
1,100,309 Common Stock
Feb 18 2023
BUY
Exercise of conversion of derivative security
-
27,848 Added 2.41%
1,128,157 Common Stock
Dec 13 2022
SELL
Open market or private sale
$1,819,565 $55.0 p/Share
33,083 Reduced 2.92%
1,100,309 Common Stock
Mar 09 2022
BUY
Exercise of conversion of derivative security
$110,547 $2.84 p/Share
38,925 Added 3.32%
1,133,392 Common Stock
Feb 24 2022
SELL
Open market or private sale
$1,166,270 $51.63 p/Share
22,589 Reduced 2.02%
1,094,467 Common Stock
Feb 23 2022
BUY
Exercise of conversion of derivative security
-
22,589 Added 1.98%
1,117,056 Common Stock
Feb 22 2022
SELL
Open market or private sale
$1,541,610 $55.36 p/Share
27,847 Reduced 2.48%
1,094,467 Common Stock
Feb 18 2022
BUY
Exercise of conversion of derivative security
-
27,847 Added 2.42%
1,122,314 Common Stock
Jan 10 2022
SELL
Open market or private sale
$1,712,289 $40.87 p/Share
41,896 Reduced 3.69%
1,094,467 Common Stock
Jan 08 2022
BUY
Exercise of conversion of derivative security
-
41,896 Added 3.56%
1,136,363 Common Stock
Oct 18 2021
SELL
Open market or private sale
$327,680 $40.0 p/Share
8,192 Reduced 0.74%
1,094,467 Common Stock
Oct 15 2021
SELL
Open market or private sale
$1,615,680 $40.0 p/Share
40,392 Reduced 3.54%
1,101,584 Common Stock
Oct 15 2021
BUY
Exercise of conversion of derivative security
$3,053 $2.84 p/Share
1,075 Added 0.1%
1,102,659 Common Stock
Oct 14 2021
SELL
Open market or private sale
$56,640 $40.0 p/Share
1,416 Reduced 0.12%
1,141,976 Common Stock
Aug 23 2021
BUY
Exercise of conversion of derivative security
$28,400 $2.84 p/Share
10,000 Added 0.87%
1,143,392 Common Stock
Feb 19 2021
SELL
Open market or private sale
$1,088,539 $39.09 p/Share
27,847 Reduced 2.4%
1,133,392 Common Stock
Feb 18 2021
BUY
Exercise of conversion of derivative security
-
27,847 Added 2.34%
1,161,239 Common Stock
Jan 11 2021
SELL
Open market or private sale
$1,334,388 $31.85 p/Share
41,896 Reduced 3.56%
1,133,392 Common Stock
Jan 08 2021
BUY
Exercise of conversion of derivative security
-
41,896 Added 3.44%
1,175,288 Common Stock
Jan 04 2021
SELL
Open market or private sale
$1,506,789 $31.17 p/Share
48,341 Reduced 4.09%
1,133,392 Common Stock
SM

Sharon Mates

Chairman and CEO
New York, NY

Track Institutional and Insider Activities on ITCI

Follow Intra-Cellular Therapies, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITCI shares.

Notify only if

Insider Trading

Get notified when an Intra Cellular Therapies, Inc. insider buys or sells ITCI shares.

Notify only if

News

Receive news related to Intra-Cellular Therapies, Inc.

Track Activities on ITCI